384 PATENT ABSTRACTS

8702988

T - C E L L L Y M P H O T R O P H I C V I R U S P R O T E I N A N D A S S A Y

Myron E ESSEX. Jonathan S ALLAN. Tun- Hou LEE assigned to PRESIDENT AND FEL- LOWS OF HARVARD COLLEGE

Cells infected with HTLV-III yield a protein (p27) having an apparent molecular weight of about 27,000 daltons. The presence in a bio- logical specimen of p27 antigenic determinants, or antibodies to p27 antigenic determinants is useful information (by itself or as a panel of tests) for predicting the course of HTLV-III infection in seropositive patients. Polypeptides and anti- bodies used to perform assays to provide that in- formation are disclosed, as well as assays and kits for such assays,

8702989

A I D S V I R U S G E N E E X P R E S S I O N

Anna ALDOVINNI, Christine Marie DEBOUCK, Martin ROSENBERG, FIossie WONG-STAAL assigned to THE UNITED STATES OF AMERICA as represented by THE; SMITHKLINE BECKMAN COR- PORATION

The tat-3 gene of HTLV-Ill is expressed at high levels in E. coli and is reactive with antibodies in- duced in response to infection by HTLV-III and can induce production of antibodies which are reactive with HTLV-III.

8702990

M A M M A L I A N I N T E R L E U K I N - 4

Frank LEE, Takashi YOKOTA, Ken-ichi ARAI. Timothy MOSMANN, Donna REN- NICK, Craig SMITH assigned to SCHERING- BIOTECH CORPORATION

Mammalian proteins and muteins thereof, designated interleukin-4s (IL-4s), are provided which exhibit both B cell growth factor activity and T cell growth factor activity. Compounds of the invention include native human and murine IL-4s. muteins thereof, and nucleic acids which are effectively homologous to disclosed cDNAs, and/or which are capable of coding for mam- malian IL-4s and their muteins.

8703096

M O N O C L O N A L A N T I B O D Y F O R R E C O V E R Y O F L E U K O C Y T E S IN

H U M A N P E R I P H E R A L B L O O D A N D M E T H O D O F R E C O V E R Y

E M P L O Y I N G S A I D M O N O C L O N A L A N T I B O D Y

Kenneth H KORTRIGHT. David E HOF- HEINZ assigned to COULTER CORPORA- TION

A murine monoclonal antibody which selec- tively binds to the determinant site or specific epitope of glycophorin A exposed on the mem- brane of the erythroeyte and does not bind to other glycophorins. The monoclonal antibody is coated on a microsphere or substrate of a suitable monodispersed variety and utilized in a separation procedure for recovery of white blood cell subsets without lysing of erythrocytes. The bound mierospheres are recovered without adverse depletion of the white blood cell popula- tion of the sample. The microsphere or bead-to- cell ratio employed is most acceptable for commercial applications of the invention. The invention thus enables accurate assaying of white blood cell subsets in circulating peripheral blood without resorting to lysing of erythrocytes.

8703200

G L U C O S E T O L E R A N C E F A C T O R A N D M E T H O D O F M A K I N G

S A M E

David HWANG, Arye LEV-RAN, Ken (deceased) BARSEGHIAN assigned to BAR- SEGHIAN Temma Legal representative of BARSEGH; ANHEUSER-BUSCH COM- PANIES INC;

A glucose tolerance factor which reduces blood sugar in mammals and is derived from yeast. The glucose tolerance factor can be isolated from autolyzed brewer's yeast extract by sequential fractionation on Sephadex G-75, Biogel P-6. Biogel P-2, to give a purified glucose tolerance factor. By further purification, a substantially purified glucose tolerance factor is obtained which is a quinoline derivative with a molecular ion at 174 by mass spectrometry,